Conclusively, our current study observed the immuno-suppressive role of BAP1 loss in PDAC, elucidated a previously undisclosed mechanism whereby BAP1 regulates cancer immunity through HSF1 repression, and provided a theoretical basis for combining SIRT1 inhibitors with ICB therapy for BAP1-deficient PDAC. Here, SIRT1 is linked to cancer.